Strongbridge Biopharma plc Announces Shareholder Approval of Proposed Acquisition by Xeris Pharmaceuticals, Inc.

NEXT STORY
Turning Point Therapeutics Announces Early Clinical Data for Repotrectinib in NTRK Fusion-Positive Advanced Solid Tumors Selected for Late-Breaker Plenary Presentation at 2021 AACR-NCI-EORTC Conference
PREV STORY
Inventiva announces the initiation of its pivotal Phase III clinical trial evaluating lanifibranor in NASH
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Globus Medical Announces CE Mark for Excelsius GPS™

AUDUBON, Pa., Jan. 05, 2017 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading ...

author_avatar
NASDAQ Market News

Mersana Therapeutics to Present Interim Phase 1 Data on XMT-1522 at the 2018 American Society of Clinical Oncology Annual Meeting

Conference Call Featuring Principal Investigator Erika Hamilton, MD to be Held Monday, June 4, ...

author_avatar
NASDAQ Market News

ERYTECH Strengthens Executive Team with the Appointment of Alex Dusek as VP of Commercial Strategy

LYON, France, May 14, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext:ERYP) (Nasdaq:ERYP), a clinical-stage ...

author_avatar
NASDAQ Market News